🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Disc Medicine, Inc. (IRON)
NASDAQ: IRON · Real-Time Price · USD
78.47
+1.90 (2.47%)
Nov 18, 2026, 12:51 PM EST - Market open
← View all transcripts

UBS Global Biopharma Conference 2026

Nov 17, 2026

Summary

Bitopertin met all Phase III EPP endpoints, with resubmission expected by year-end 2026 and FDA action targeted for mid-2027. Phase II programs target myelofibrosis anemia, IBD anemia and polycythemia vera, with further data and development plans expected at ASH and in 2027.

Joon Lee
Biotech Analyst, UBS

All right. I guess we will get started. Thank you. Thank you for joining our inaugural UBS Global Biopharma Conference 2026. My name is Joon Lee, one of the biotech analysts at UBS. For this session, we have John Quisel, CEO of Disc Medicine. John, thank you so much for spending your time with us. For the audience who may be new to the story, could you just give a quick intro about your company, yourself, and why investors should be paying attention to Disc Medicine?

John Quisel
CEO, Disc Medicine

Yeah, thank you. It is great to be here. Disc Medicine, we have been public for about four years, and we focus on manipulating metabolic pathways in red blood cells and erythrocytes to address a wide range of hematologic disorders that arise in the red blood cell compartment. We have three clinical stage programs, all focusing on controlling either heme or iron metabolism, again, to address diseases that arise in the red blood cells. Our lead program just had a prominent phase III readout, successful, excellent readout across all the endpoints in a rare disease called erythropoietic protoporphyria. Then we have two pipeline programs that are in phase II, proof of concept achieved, progressing towards phase III, and they are in the myeloproliferative disease space.

Joon Lee
Biotech Analyst, UBS

Congrats on all the success. Let us start from the basic. Tell us a little bit about EPP and XLP and what the unmet needs are and how bito could fill that unmet need based on the data that you have.

John Quisel
CEO, Disc Medicine

Sure. These are porphyrias, erythropoietic protoporphyria, EPP, and then a closely related disease, different genotype, but same phenotype called XLP or X-linked protoporphyria. These are both diseases that are caused by genetic mutations in enzymes of the heme biosynthetic pathway. When those enzymes are deficient, you get a buildup of metabolites that are produced in the process of heme biosynthesis, which many people do not realize, this is one of the single most active biosynthetic pathways in the human body because there is a tremendous amount of red blood cell production happening all the time. Every red blood cell has a tremendous amount of heme in it. So it is this high velocity, high volume pathway, and when it is broken genetically, you get these metabolites that just spew out of the red blood cells and create toxic side effects. In this case, the key metabolite is called protoporphyrin IX.

It's the last metabolite of the pathway, and this metabolite does two things that are quite damaging to the body. In the first instance, it absorbs light energy, and so when a patient whose blood is full of this chemical goes out into the sunlight, that sunlight activates the protoporphyrin IX, which becomes a free radical and essentially starts to burn the patient from the inside of the bloodstream. It's excruciatingly painful. These pain attacks are reported as being like having lava flowing through the blood, and takes days for these pain attacks to resolve. Needless to say, after a few of these attacks, patients essentially retreat into the darkness and choose their entire career, hobbies, et cetera, built around being in the dark.

A life-changing and profound disease. The second thing that the protoporphyrin IX does is it accumulates in the hepatobiliary system, causing backing up and leading to liver damage. The liver in these patients can turn purple. With the buildup of protoporphyrin IX. While about a third of patients will have some evidence of liver damage, 2%-5% will go into overt liver failure, obviously a very serious consequence of the disease.

Joon Lee
Biotech Analyst, UBS

There is a drug approved for the hepatic porphyria.

John Quisel
CEO, Disc Medicine

There is, that's right. Well, that's a different disease.

a different kind of phenotype, but it's another mutation in the heme biosynthetic pathway that leads to a different toxin building up in the body. You're correct, because there, the target organ is the liver.

siRNA from Alnylam, called GIVLAARI, has been effective in the hepatic porphyria space.

Joon Lee
Biotech Analyst, UBS

Sounds like a horrible disease, and you hit all endpoints on phase III APOLLO this time. It will be a resubmission. What made this work, this trial work, as opposed to prior trial, which missed the endpoint?

John Quisel
CEO, Disc Medicine

Yeah. So we had a phase II program, as you say. We were in the process of getting accelerated approval.

before things went sideways in a fairly dramatic way. But actually, the primary endpoint hit, and if you look at the active arm in phase II, the results were amazing. Patients were spending more time in light. They were having close to 75% fewer pain attacks.

They reported, I think all but one patient reported feeling much better on therapy. Many of those endpoints were nominally stat sig. What made it challenging is that in the first secondary endpoint, the placebo group outperformed and destroyed the stat sig, but there was not power for that endpoint in phase II. There, the powering was around measuring the toxic metabolite, which we clearly decreased, that was stat sig. So we hit our primary in the phase II program, and that is what led to the possibility of an accelerated approval.

While eventually that didn't work out, we were able to take our learnings from phase II, power the study appropriately now to capture the clinically meaningful endpoints. It's very satisfying to see that we designed the trial well, and we were able to actually hit what are some pretty difficult endpoints in terms of measuring patients' tolerance to sunlight, the time they're choosing to spend in sunlight. These were the critical endpoints to hit, and we hit all of them.

Joon Lee
Biotech Analyst, UBS

Congratulations again on that phase III hitting on all the endpoints. You're planning for NDA submission by year-end. How's that going?

John Quisel
CEO, Disc Medicine

Going well, yeah. It's technically what's called a resubmission, right? We have the CRL, we resubmit. That sets up a six-month review period. We expect to get that resubmission done before the end of the year, and then if you tack six months onto that means we should get the regulatory action by the middle of next year.

Joon Lee
Biotech Analyst, UBS

Got it. Are you expecting an AdCom?

John Quisel
CEO, Disc Medicine

We're not. I suppose you never know. It is a novel mechanism, but there was no talk of that the first time around. In many ways, we would probably welcome that. We know that we have tremendous support from the KOL community, tremendous support from the patient community. I think in an AdCom, you have one of these situations where it's highly enthusiastic.

Joon Lee
Biotech Analyst, UBS

Yeah, it's life-changing for some of these patients, right?

John Quisel
CEO, Disc Medicine

It is. One of the things that happened after we didn't get approval-

Joon Lee
Biotech Analyst, UBS

Yeah

John Quisel
CEO, Disc Medicine

on the accelerated path is the patient groups became very motivated. I mean, I think it was very frustrating and upsetting to them that they weren't going to have access to this therapy right away, and they became highly active. You've seen now many patients coming out in the media to talk about the story of having this disease, and even some of them talking about the experience of being on our trial and relating pretty much uniformly the story as one of a life-changing event, where you have people who are able to do things with their families that they've never been able to do before, fishing, running marathons, going to the beach, things we all just take for granted that now are first-in-a-life experiences.

Joon Lee
Biotech Analyst, UBS

Have you had a pre-NDA meeting yet, or is there a plan for one before you submit the NDA?

John Quisel
CEO, Disc Medicine

Well, I mean, we did all of that back in the first go-round.

Joon Lee
Biotech Analyst, UBS

Got it.

John Quisel
CEO, Disc Medicine

The core principle is really just the resubmission. We're in contact with the FDA, working to get some dialogue and see anything we can do to potentially make things go faster. But fundamentally, the next step is really just the resubmission.

Joon Lee
Biotech Analyst, UBS

Got it. Potentially a launch in 2027, mid-2027. Is that a fair assumption?

John Quisel
CEO, Disc Medicine

Yeah.

Joon Lee
Biotech Analyst, UBS

You only get one chance to launch a drug. What are you doing between now and mid-2027 to make sure it's a good launch?

John Quisel
CEO, Disc Medicine

Yeah, there's a lot of work. Because we thought we might be launching in February, the past February, we already did quite a bit of work building up. While we did have to sadly let go of some of the commercial team around the CRL, we did retain about half of them. So we have about half the sales team that's been in the field the whole year, and the knowledge we have of this market now has improved dramatically. The goal of that team, obviously, they can't directly market the product, but they can talk to physicians, raise disease awareness, build out the story, understanding that protoporphyrin IX is the root cause of this disease. We've learned a lot from that. We've learned, for example, we want to ensure that there's no barriers to diagnosis, right?

The key to diagnosis, it's actually a very simple biochemical test, been around, but you have to know the right test, the right place to order it from for PPIX, and we've now been able to set up a program to just make diagnosis efficient for these patients. So that's one of the learnings. We've learned that while there is a set of patients at the centers of excellence, there's also a long tail that are in the community. So we've built out structures to help doctors in the community understand this disease and create a peer-to-peer group of doctors who are kind of motivated to increase awareness and education and elevate the patient care standards for this disease state out in the community as well. Strategies to Our core strategy, sales force expected to be about 24 reps.

That's to target, first and foremost, the top 100 sites. I mean, they're going to be able to target about 1,000 providers who cover probably about, predicted about 6,000 patients. But these various strategies we're doing will also access what we think is a long tail of patients to get to the 14,000 that you can see in the claims databases in the U.S.

Joon Lee
Biotech Analyst, UBS

You mentioned about 6,000 patients in the U.S. We get some different numbers, right?

John Quisel
CEO, Disc Medicine

Yeah.

Joon Lee
Biotech Analyst, UBS

There's a range of patients, and it's not uncommon for a rare disease to have confusing prevalence numbers, incidents, and because there was nothing available, and so nobody bothered to do a study. So where do you get that 6,000, and how do you make sense of that vis-a-vis the published cases in the literature and the upside, right? Because if you start looking, there might be more, and you can extrapolate from that. Tell us a little bit about the range.

John Quisel
CEO, Disc Medicine

Yeah. The core to our analysis has been using claims data. We've used the Komodo database, and which, by the way, anyone can access. If you pay for it, you can go do the research yourselves. We and others all uniformly see about 14,000-15,000 patients who have used There's an ICD-10 code for this disease specifically that came into existence, I want to say, about eight years ago. There's about 15,000 patients in the U.S. who've had a claim against this code. So that represents a pool of patients who probably have had diagnosis.

If you look, we and others have taken various approaches to slicing and dicing that 14,000-15,000 to try to define who might be approachable earlier, and who might be real, right? Because there is going to be some degree of inaccuracy in the claims data. What we have found useful is to look at those patients who had a claim in the last three years.

We call that the engaged patient population. That is where we get our 6,000 number from. There are other analyses you can do. You can say, "How many people have had multiple claims against this code?" That turns out to get you to a number of 3,000 to 4,000, depending on who is doing the analysis. Before we came into the field, the academic literature suggested roughly one in 100,000, so that would get you to a 3,000 to 4,000 number for the U.S. If you look at the academic genetic literature, it actually suggests 20,000 patients with the genotype.

I think you can see a span running from about 4,000 at the low end to about 20,000 at the high end, and we are designing our sales force to focus on probably a 4,000 to 6,000 engaged patient population at the outset. We also have other ways of trying to access and mobilize what we think is up to about 14,000-15,000 patients.

Joon Lee
Biotech Analyst, UBS

Is that ICD-10 code specific to EPP or XLP, or what is actually the language of that ICD-10 code?

John Quisel
CEO, Disc Medicine

Oh, I'm not sure I could replicate that, but it's EPP and XLP.

Joon Lee
Biotech Analyst, UBS

Okay.

John Quisel
CEO, Disc Medicine

I believe it also includes a very severe, rare form of porphyria called CEP.

Joon Lee
Biotech Analyst, UBS

Okay.

John Quisel
CEO, Disc Medicine

And that's it.

Joon Lee
Biotech Analyst, UBS

Yeah. So it's not like NOS, not otherwise specified type of ICD code where it could be used for a variety of other things that are not

John Quisel
CEO, Disc Medicine

No, that is right. Actually, again, one of the hypotheses out there is that, well, the 14,000 with one claim

Joon Lee
Biotech Analyst, UBS

Yeah

John Quisel
CEO, Disc Medicine

those are sort of rule-out claims.

Joon Lee
Biotech Analyst, UBS

Yeah, exactly.

John Quisel
CEO, Disc Medicine

Right? Actually, when we put our numbers together, we scraped out any patient who had the one claim for EPP multiple claims for some other sun-related disorder.

Joon Lee
Biotech Analyst, UBS

Yeah.

John Quisel
CEO, Disc Medicine

Right? We've already removed those patients.

Joon Lee
Biotech Analyst, UBS

Yeah.

John Quisel
CEO, Disc Medicine

Someone who comes in and says, "Hey, Doc, I can't tolerate sunlight," there's a whole diagnostic journey there. Several different types of diseases it might be. Those are already missing from our 14,000 number.

Joon Lee
Biotech Analyst, UBS

I'm glad to hear that, because in the medical field, I think people are encouraged to check as many ICD-10 codes as possible for the billing purposes.

John Quisel
CEO, Disc Medicine

Right. What I will say is even if you want to take a worst-case scenario and assume 3,000, 4,000 patients, put your penetrance and your price numbers on there, you'll find out that this is, in the worst-case scenario, going to be a very good rare disease market.

Joon Lee
Biotech Analyst, UBS

GIVLAARI for hepatic porphyria, relative to that, how much bigger is EPP and XLP?

John Quisel
CEO, Disc Medicine

It is bigger. GIVLAARI is kind of restricted to a label only for a subset population who have, I forget what, it's some degree of frequency or severity of the attacks that characterize that disease. There's a very effective therapy that's given to patients during an attack.

Joon Lee
Biotech Analyst, UBS

Yeah.

John Quisel
CEO, Disc Medicine

I think there's a variety of reasons that market is a little bit more complicated and smaller than we expect.

Joon Lee
Biotech Analyst, UBS

Yeah.

John Quisel
CEO, Disc Medicine

If you look at the launch, the uptake was fantastic. It just kind of reached a plateau and capped out. We think we're going to see, again, similar sense of pent-up demand, then we think there's a, like I mentioned, a long tail of patients who will come into the healthcare system once there's a good oral therapy available.

Joon Lee
Biotech Analyst, UBS

Yeah, despite the small market size, doing well, priced very robustly, actually.

John Quisel
CEO, Disc Medicine

Yeah.

Joon Lee
Biotech Analyst, UBS

How are you thinking about pricing for this indication?

John Quisel
CEO, Disc Medicine

Well, to your point, there is one approved drug for EPP patients, a surgically implanted drug priced around $300,000 a year.

Joon Lee
Biotech Analyst, UBS

Yeah.

John Quisel
CEO, Disc Medicine

Then if you look over in the hepatic porphyria, GIVLAARI, which is more of a disease-modifying, getting to the root cause, mechanistically, it targets the heme biosynthetic pathway just like bitopertin does, and that is priced closer to $600,000 a year.

Joon Lee
Biotech Analyst, UBS

Yeah.

John Quisel
CEO, Disc Medicine

Which I think is actually, if you look at the kind of graphs you can see of disease rarity versus the pricing across all rare diseases, GIVLAARI sits kind of on that graph. These are the guideposts in the porphyria space that you can think about. Obviously, we will need to get our label before we can actually come out with a price, a specific price guidance, but that gives you a sense of the precedents that are out there.

Joon Lee
Biotech Analyst, UBS

Right. You have some work ahead of you, ahead of launch. We will be watching that closely. While you prepare for the launch of that lead drug, you have other pipeline programs, hepcidin modulation programs. Could you tell us a little bit about your lead drugs and the recent data from phase II RALLY-MF, myelofibrosis?

John Quisel
CEO, Disc Medicine

Yeah. Yeah, thanks. Our pipeline, two phase II programs that are both working on controlling iron. One is what you can think of as mobilizing iron, and this is what we used to call DISC-0974. Now it has a generic name, selcodebart. That is in, as you mentioned, a phase II trial called the RALLY-MF trial, enrolling about 90 patients. What is remarkable is anemia of MF, this has been something that people have been working on for decades, and there is still no approved product that treats the anemia in these patients. It is a very persistent, severe anemia. It is top of the list for one of the things doctors would like to be able to manage.

If you look at some of the therapies that are given to address the disease, like JAKi, ruxolitinib, they actually exacerbate the anemia, and so anemia represents not only a primary aspect of the disease that needs to be managed, but also a secondary aspect of the disease that limits the ability to use other drugs.

Right? Ruxolitinib is often not usable because of the anemia. That has given rise to then a set of anemia-sparing products like momelotinib and pacritinib, all focused on suppressing JAK inhibition. But again, stepping back, we're just saying, "Look-" There's evidence from some early publications at the Mayo Clinic that hepcidin is quite elevated in these patients, leading to an iron-restricted anemia.

Classically called anemia of inflammation, meaning that the patient's bodies will have iron in it, but that iron is not available to the red cells as they're forming. Every red cell needs heme, which is made of, in part, iron. So you simply can't make adequate hemoglobin red cell production without iron availability. Our drug, in a very selective, specific way, suppresses hepcidin and allows the bone marrow to access the iron stores in the body. So there was a hypothesis from many years ago that this might be effective in these patients. In fact, what we've seen is, at this point, unambiguous. It's a remarkable response rate. We have individual patients who've been normalized. We have one patient who came into the study at around 7 grams per deciliter, got back to their baseline pre-disease level of 13, 14 grams. So remarkable kind of effects.

On average, what we see is about what's called a major response rate, so the most stringent response rate of ballpark 50%. What's really satisfying is that we see that it doesn't really matter what kind of patient you are. If you have anemia of myelofibrosis, our drug appears to show efficacy, and in that 50% range. So early-stage patients who are not yet requiring transfusions but are nonetheless affected by their anemia, fatigue, et cetera, those patients experience a great response rate. Patients who are being initially transfused, patients who are heavily transfused, we see responses across all those. Then really importantly, we see responses in patients who are on ruxolitinib, right? So these are patients whose anemia is being exacerbated by the therapy that they're on.

You put them on our drug, and you see a nice anemia response, which now, while we're not testing this directly, should allow doctors then to have greater flexibility in how they use some of these JAK2 targeted therapies as well. The way that all rolls up is that these are all our phase II data. We expect we'll have an oral presentation at ASH.

We are having an end of phase II meeting with the FDA. We will read out the results of that at ASH, so we should be able to provide the There is really no doubt that we are progressing to phase III, but we will be able to provide what the phase III design looks like. The goal, based on our data, is really to cover the entire set of anemic MF patients, again, who have no approved therapeutic option. Everything that is used is kind of bits and pieces of off-label EPO, off-label danazol.

We put that all together, there is about 22,000 anemic MF patients in the U.S. I think price point's a good analog here would be luspatercept, which manages anemia in MDS patients. Actually, they ran a trial in myelofibrosis with that drug. It failed.

Joon Lee
Biotech Analyst, UBS

Yeah.

John Quisel
CEO, Disc Medicine

They are going to seek approval anyway in the narrow population of patients who are most heavily transfused and on ruxolitinib. I think it represents a very significant opportunity and a very significant unmet medical need.

Joon Lee
Biotech Analyst, UBS

Don't you have a history with luspatercept?

John Quisel
CEO, Disc Medicine

I do. I was previously, thanks for mentioning that, proudly and previously at Acceleron Pharma for about 14 years, where we created luspatercept, initially got it approved in beta-thal MDS, and then also sotatercept in PAH.

Joon Lee
Biotech Analyst, UBS

You know the space.

John Quisel
CEO, Disc Medicine

Yeah, yeah. No, it's been fascinating to see the way the regulatory environment has evolved. You see a lot of urgency from the regulators really wanting to work with the KOL community to find a way to address anemia in MF patients. I think there's a lot of desire to collaborate there, because as I mentioned, this has been a decades-long search.

for a drug that would do this. The IMiD class of drugs was explored here, didn't work. Luspatercept now has been explored. EPO's been explored. Everything has just been, it's just a really tough anemia. It's just been so satisfying to find out that simply mobilizing iron.

Joon Lee
Biotech Analyst, UBS

Yeah

John Quisel
CEO, Disc Medicine

which is a very straightforward and what appears to be quite safe mechanism, that turned out to be the hidden key.

Joon Lee
Biotech Analyst, UBS

That's biology.

John Quisel
CEO, Disc Medicine

Yeah, yeah.

Joon Lee
Biotech Analyst, UBS

Yeah. So let's just think more bigger opportunities, right? So you have another study in phase II for anemia of inflammation that includes-

John Quisel
CEO, Disc Medicine

Correct

Joon Lee
Biotech Analyst, UBS

IBD.

John Quisel
CEO, Disc Medicine

Right, right.

Joon Lee
Biotech Analyst, UBS

That's a huge opportunity there. When are we going to see some data, and what kind of expectations are you setting for the investors?

John Quisel
CEO, Disc Medicine

Yeah, so anemia of inflammation, broadly speaking, has been, again, a target for decades. It's always been known that there are these patients who have an anemia that simply doesn't respond to EPO. They have enough iron in their body, so it's not appropriate to give IV iron. It's been called the anemia of inflammation because it's often an inflammatory disease process that elevates hepcidin, which restricts the iron availability in the body. So it's always been an intent for us to pursue that whole broad area with this mechanism.

The way we approached this is to take a variety of animal models and start to explore those, then where we see strong evidence of activity to then open up a clinical trial as a kind of signal-seeking study. One of the animal models we've looked at is inflammatory bowel disease. We've now done multiple models. All of the data are actually quite remarkable. We see essentially complete resolution of anemia-

and even signs of some benefit on the inflammatory disease phenotype as well, which is fascinating. Based on that strong data, as well as the evidence from myelofibrosis that in a high hepcidin disorder, you get a great effect on anemia, we opened up a phase II program in the IBD anemia space. That trial's been plugging away. We'll have data next year. We haven't guided. As we come in towards the end of the year, either at ASH or maybe at JP Morgan, we'll

Joon Lee
Biotech Analyst, UBS

Yeah

John Quisel
CEO, Disc Medicine

tighten up our guidance plan for 2027. But right now, it sits there on the calendar as sometime next year, we'll be able to provide some data from that study.

Joon Lee
Biotech Analyst, UBS

Real pipeline in a drug kind of opportunity. The last drug I want to talk about is DISC-3405. This is for polycythemia vera, I believe. You have data. Tell us a little bit about that program and what you're going to do with that, given the competitive landscape, especially.

John Quisel
CEO, Disc Medicine

Yeah. Right. Exactly. Well, I think this is a really exciting emerging therapeutic area, right? Polycythemia vera, characterized by excess red blood cell production, driven largely by JAK2 mutations. It's well-known scientifically that iron actually interacts with the JAK2 EPO signaling pathway. If you restrict iron, which is the opposite of what we're doing in myelofibrosis

Joon Lee
Biotech Analyst, UBS

Yeah

John Quisel
CEO, Disc Medicine

where we're relieving this, now we're restricting it. The targets are essentially the on and off switches genetically defined in the body. No surprise, the selcodebart program is the on switch for iron.

Joon Lee
Biotech Analyst, UBS

Yeah

John Quisel
CEO, Disc Medicine

The DISC-3405 program is the off switch for iron. The underpinnings, the basic science here are very simple, well-known. If you restrict iron in a PV patient, that will shut down that hyperactive JAK2 signaling pathway and essentially normalize or reduce the red cell production.

The therapeutic objective is to bring that down to about a hematocrit of 45% or less, so the patients are relieved of the risk of thromboembolic events. That's the main complication you're trying to avoid. The mainstay therapy has been phlebotomy, right? Phlebotomy obviously mechanically removes red cells, but the reason it's used is because when you remove enough red cells, you are removing iron. By repeated phlebotomy, you can eventually induce a state of iron deficiency in these patients. Literal, like they don't have enough iron in their bodies. That will, as I mentioned, control that red blood cell production, achieve, you can get to a target hematocrit that way. But that iron deficiency that you get is very uncomfortable for patients, right? Like any of us, if we become iron deficient, it is not a good way to live your life.

Joon Lee
Biotech Analyst, UBS

Yeah.

John Quisel
CEO, Disc Medicine

It leads to brain fog, it leads to itchiness. It leads to a lot of sequelae that have often been characterized as parts of the PV disease. Now we've had the first iron restriction agent, called rusfertide, is now approved.

Joon Lee
Biotech Analyst, UBS

Yep.

John Quisel
CEO, Disc Medicine

As a pioneer, they did a fantastic job, and they proved out that actually many of the symptoms that were thought to be fundamental to PV look to be relieved when you actually just give people a drug that you can now avoid the phlebotomy. The body starts to recover its ability to access this iron, but this hepcidin-based drug denies the iron to the red blood cell compartment. That is the key thing here. What we are doing with our DISC-3405 program against TMPRSS6, you are elevating the body's hepcidin, and what that does is you avoid phlebotomy, meaning you do not have to take iron out of the body anymore. The patient's body gets to keep its iron, but now that iron is no longer available to the red blood cell compartment. So you get hematocrit control-

the same as you do with phlebotomy, but now you do not have to live with the consequences of iron deficiency. The brain, et cetera, can access that iron. This looks like a really promising approach. There are probably 75, somewhere between 50 and 100,000 patients in the U.S. who have polycythemia vera who are being managed chronically, lifelong phlebotomy-

to keep this under control. They live with then this whole set of side effects that come from iron deficiency. Now we understand that if you give a hepcidin-based drug, you can achieve the same level of hematocrit control, but you allow a lot of symptomatic quality of life improvement in these patients. We have seen now the price point for that rusfertide program sits at around, it has some weight-based dosing, but roughly call it $250 thousand per year. You put that together with 50 to 100,000 patients, and you can see this is going to be a large and important rare disease market.

Joon Lee
Biotech Analyst, UBS

Your target is validated.

John Quisel
CEO, Disc Medicine

Yeah.

Joon Lee
Biotech Analyst, UBS

Your drug is approved. That's a weekly subcu injection, I believe?

John Quisel
CEO, Disc Medicine

What we showed at SOHO in September

Joon Lee
Biotech Analyst, UBS

Yeah

John Quisel
CEO, Disc Medicine

is cohort A

Joon Lee
Biotech Analyst, UBS

Yeah

John Quisel
CEO, Disc Medicine

which is a Q2 weeks injection.

Joon Lee
Biotech Analyst, UBS

Okay.

John Quisel
CEO, Disc Medicine

What we're going to show at ASH, the oral presentation is going to be a Q4 weeks.

Joon Lee
Biotech Analyst, UBS

Okay

John Quisel
CEO, Disc Medicine

It's an antibody, monoclonal antibody.

Joon Lee
Biotech Analyst, UBS

Yeah. Q4 weeks, then there's also an siRNA in development that is Q12 weeks. Where do you see this slotting in and be competitive? Is this going to be like some people might want this versus that, and you're going to settle on some reasonable percentage market share, or?

John Quisel
CEO, Disc Medicine

Right. Yeah. There's, as I mentioned, one peptide drug. Which requires weekly or even more frequent dosing. That is the one approved agent here. Then we have three different programs behind that, all targeting the TMPRSS6 target.

Joon Lee
Biotech Analyst, UBS

Yeah.

John Quisel
CEO, Disc Medicine

The promise of that approach is perhaps achieving less frequent dosing plus a more patient-friendly side effect profile. Two of those programs are nucleic acids. One is an siRNA, one is an antisense.

Joon Lee
Biotech Analyst, UBS

Yeah.

John Quisel
CEO, Disc Medicine

We are the only antibody. What we believe that we will achieve with our antibody is, and we will show this at ASH, but we think we can do a monthly dosing, should be straightforward based on the phase I data.

Joon Lee
Biotech Analyst, UBS

Yeah.

John Quisel
CEO, Disc Medicine

We think we will be able to create a self-administered auto-injector type presentation. What you get with an antibody, just everything is very predictable.

Joon Lee
Biotech Analyst, UBS

Yeah.

John Quisel
CEO, Disc Medicine

The PK/PD effects are all easy to measure. You do not expect to get injection site reactions, which has been something of an issue with some of the other programs. We also do not expect to get anemia. Now, anemia is the opposite of polycythemia, right? The polycythemia disease state is excess red cell production.

Joon Lee
Biotech Analyst, UBS

Yeah.

John Quisel
CEO, Disc Medicine

But as you restrict iron, you can drive If you restrict iron completely, you can take a PV patient and make them anemic.

Joon Lee
Biotech Analyst, UBS

Yeah.

John Quisel
CEO, Disc Medicine

Right? That is something that I think all of these programs are going to see to some degree, because you are basically trying to ratchet down iron and trying to ratchet down red blood cells. If you overcorrect-

Joon Lee
Biotech Analyst, UBS

Yeah

John Quisel
CEO, Disc Medicine

you will end up with an anemic side effect. I think the promise of an antibody is that if you hit anemia, you just skip a dose.

Joon Lee
Biotech Analyst, UBS

Yeah.

John Quisel
CEO, Disc Medicine

And within a matter of weeks, it will reverse itself, right?

Whereas some of these approaches that have a very persistent effect, the data remains to be seen, but I think the issue you may have is patients who are plunged into anemia, but then can't be reversed for months on end.

Joon Lee
Biotech Analyst, UBS

Yeah.

John Quisel
CEO, Disc Medicine

So we think that an antibody approach should present a very patient-friendly way of dosing that. I think the efficacy across the board is going to be all the same. Now, probably we more than anyone needs to prove that out still, but I think all of them are going to achieve the same level of iron restriction.

Joon Lee
Biotech Analyst, UBS

Yeah.

John Quisel
CEO, Disc Medicine

And the question is going to be who has what approach is just the friendliest to patients?

Joon Lee
Biotech Analyst, UBS

How much does the iron fluctuate as a normal course of the day or the week or depending on diet, exercise, environment?

John Quisel
CEO, Disc Medicine

Iron does fluctuate. It's a great question. I mean, it's known that iron, if you just look at serum iron level across a day, it'll fluctuate over just the period of a day. Then on this timescale of months, diet can have an effect for sure, then you have an underlying disease, which can also fluctuate.

Joon Lee
Biotech Analyst, UBS

Yeah. So I guess that is a case for an antibody that you can actually withdraw if needed and be more flexible.

John Quisel
CEO, Disc Medicine

Yeah.

Joon Lee
Biotech Analyst, UBS

All right, we're out of time.

John Quisel
CEO, Disc Medicine

We are out of time.

Joon Lee
Biotech Analyst, UBS

Last comment before we adjourn.

John Quisel
CEO, Disc Medicine

Well, we are just tremendously excited that our approach of targeting red cell metabolism appears at this point to have three programs that are all working, right? One of them now proved out in phase III.

I think definitively proven. The other two, the phase II data are just clearer. The mechanisms are, I think, already to a large extent validated. I see the technical risk here across our entire pipeline of the lead three programs, lead three indications, as very straightforward, and each one just gets bigger than the one before. I think a lot of exciting opportunity for us.

Joon Lee
Biotech Analyst, UBS

Well, looking forward to seeing you at ASH, and thank you so much, everyone, for paying attention.

John Quisel
CEO, Disc Medicine

Thank you.